Together, these results suggests that DWP418-PEG-HER, which exhibits HER2-targeting ability, potent therapeutic efficacy, and safety, is a promising therapeutic for systemic treatment of HER2-overexpressing cancer. Here, ERBB2 is linked to cancer.